10-1074 vs Lotivibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV envelope · full HIV pipeline

10-1074

Developed by Gilead Sciences under a licence from The Rockefeller University

Phase 2 in HIVmonoclonal antibody
Weak signal

NCT03707977 · Phase 1/2 · completed

This was a small, nonrandomized, open-label study without a comparator arm, enrolling 30 children overall and evaluating viral-load and safety outcomes descriptively. All participants received 10-1074 together with a second antibody, VRC01LS, so the results describe the dual-antibody regimen, not 10-1074 alone. The primary viral outcomes were reported as 11 of 25 below 400 copies/mL and 10 of 25 below 40 copies/mL at Week 24, but there was no controlled comparison or formal significance test.

Reported efficacy

Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant); Severity of Treatment-associated AEs (Number of Participants With Grade 3 or Higher Related AEs) (Measured until 30 days after study completion for each participant); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 400 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 40 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2): Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant): Group PK-A: ART + VRC01LS 4 Participants | Group PK-B: ART + 10-1074 1 Participants | Steps 1-3 Participants (ART + 10-1074 + VRC01LS) 19 Participants (not_applicable)

Result source: NCT03707977

Lotivibart

Developed by ViiV Healthcare

Phase 2 in HIVmonoclonal antibody
Weak signal

NCT04871113 · Phase 2 · completed

Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.

Next expected readout: January 2027 · NCT07053384 (registry estimate)

Reported efficacy

Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Adverse Events (AEs) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase): Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69) (not_applicable)

Result source: NCT04871113

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpoint10-1074Lotivibart
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

10-1074
—Not reported
Lotivibart
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

10-1074
—Not reported
Lotivibart
—Not reported

CD4 count, change (week 48)

10-1074
—Not reported
Lotivibart
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. 10-1074: 3 of 4 rows · Lotivibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metric10-1074Lotivibart
Dropout rate
0%Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
—PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—700 mg IVa
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
—700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
12.5%3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
0%60 mg/kg
NCT05291520 · Phase 1 · monotherapy
0%20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Discontinued due to AEs
—Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
—PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—700 mg IVa
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
—700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
—60 mg/kg
NCT05291520 · Phase 1 · monotherapy
—20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Serious AEs
—Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
0%PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
0%Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
4%Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
0%700 mg IVa
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
0%700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
18.8%700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
25%700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
12.5%70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
12.5%40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
0%60 mg/kg
NCT05291520 · Phase 1 · monotherapy
0%20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Most frequent reported AEs
rhinorrhoea 83.3%
cough 50%
pyrexia 50%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 2 more results
neutrophil count decreased 35.7%
haemoglobin decreased 28.6%
cough 25%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
cough 44%
upper respiratory tract infection 32%
haemoglobin decreased 28%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
700 mg IVa
influenza 12.5%
rhinitis 12.5%
aspartate aminotransferase increased 6.3%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
700 mg SC
headache 18.8%
blood creatine phosphokinase increased 12.5%
neutropenia 12.5%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
700 mg IV
upper respiratory tract infection 18.8%
anaemia 12.5%
anogenital warts 6.3%
NCT04871113 · Phase 2 · combination · HIV · phase 2
700 mg SC
neutropenia 12.5%
pharyngitis 12.5%
tonsillitis 12.5%
NCT04871113 · Phase 2 · combination · HIV · phase 2
280 mg IV
abdominal pain 16.7%
asthenia 16.7%
bronchitis 16.7%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
280 mg IV
depression 16.7%
hypertension 16.7%
influenza like illness 16.7%
NCT04871113 · Phase 2 · combination · HIV · phase 2
70 mg IV
covid-19 12.5%
alanine aminotransferase increased 6.3%
anal abscess 6.3%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
70 mg IV
upper respiratory tract infection 12.5%
vomiting 12.5%
abdominal pain 6.3%
NCT04871113 · Phase 2 · combination · HIV · phase 2
40 mg/kg IV
abdominal pain 12.5%
blood creatine phosphokinase increased 12.5%
covid-19 12.5%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
40 mg/kg IV
covid-19 25%
proctitis gonococcal 25%
syphilis 25%
NCT04871113 · Phase 2 · combination · HIV · phase 2
3000 mg + rHuPH20
injection site erythema 100%
injection site bruising 25%
injection site pain 25%
NCT05291520 · Phase 1 · combination
60 mg/kg
medical device site dermatitis 12.5%
muscle tightness 12.5%
covid-19 0%
NCT05291520 · Phase 1 · monotherapy
20 mg/kg + rHuPH20
injection site erythema 87.5%
upper respiratory tract infection 25%
headache 12.5%
NCT05291520 · Phase 1 · combination

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lotivibart

HIV-1 RNA -25966 copies/mL @ 12wk700 mg IV
absolute change · copies/mL
No placebo or comparator arm
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 4 more results
-12584 copies/mL @ 12wk700 mg SC
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-26826.5 copies/mL @ 12wk280 mg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-14720.5 copies/mL @ 12wk70 mg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-12014.5 copies/mL @ 12wk40 mg/kg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
CD4+ -3.3 cells/uL @ 12wk700 mg IV
absolute change · cells/uL
No placebo or comparator arm
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 4 more results
-19.6 cells/uL @ 12wk700 mg SC
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
30.2 cells/uL @ 12wk280 mg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-54.3 cells/uL @ 12wk70 mg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
31.8 cells/uL @ 12wk40 mg/kg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
CD4+ 134.9 cells/uL @ 48wk700 mg IV
absolute change · cells/uL
No placebo or comparator arm
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
show 4 more results
247.3 cells/uL @ 48wk700 mg SC
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
180.4 cells/uL @ 48wk280 mg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
233.8 cells/uL @ 48wk70 mg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
140 cells/uL @ 48wk40 mg/kg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 10-1074's landscape · Lotivibart's landscape